Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/.

Details on the abstracts are as follows:

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection

Abstract #: 588
Title: Sustained reduction of HBV antigen levels at ≥6 months follow-up in HBeAg-positive participants with chronic hepatitis B infection after 96 weeks of 300 mg pevifoscorvir sodium monotherapy
Presenter: Professor Lung-Yi Loey Mak, MBBS(HK), MD(HK), MRCP(UK), PDipID (HK), FHKCP, FHKAM (Medicine), FRCP (Glasg), FRCP (Edin), FRCP, Clinical Assistant Professor at The University of Hong Kong
Date/Time: May 27, 2026 at 8:30am – 5:00pm CET
Session: Viral Hepatitis B and D: New therapies, unapproved therapies or strategies

Abstract #: 602
Title: Pevifoscorvir sodium demonstrated profound antiviral activity in untreated HBeAg+ subjects, regardless of baseline ALT level
Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
Date/Time: May 27, 2026 at 8:30am – 5:00pm CET
Session: Viral Hepatitis B and D: New therapies, unapproved therapies or strategies

Abstract #: 586
Title: Population pharmacokinetics of pevifoscorvir sodium (ALG-000184) in healthy participants and participants with chronic hepatitis B in support of phase 2 dose selection
Presenter: Kha Le, PhD
Date/Time: May 27, 2026 at 8:30am – 5:00pm CET
Session: Viral Hepatitis B and D: New therapies, unapproved therapies or strategies

Abstract #: 570
Title: ALG-001075, the parent of pevifoscorvir sodium, exhibits potent in vitro antiviral properties compared to other HBV capsid assembly modulators in clinical development
Presenter: Yannick Debing, PhD
Date/Time: May 28, 2026 at 8:30am – 5:00pm CET
Session: Viral Hepatitis: Experimental and pathophysiology

Abstract #: 634
Title: Potent and durable off-treatment reduction of HBsAg levels and cccDNA-derived transcripts by the CAM-E ALG-001075 in cell-based experiments

Schreibe Deinen Kommentar